低分子肝素联合银杏达莫注射液治疗不稳定型心绞痛的临床观察

CHnical observation on therapeutic effect of low-molecule heparin integrated with Ginkgo-dipyidamolum injection on unstable angina pectoris

目的探讨低分子肝素（LMWH）联合银杏达莫注射液治疗不稳定型心绞痛的疗效。方法选择2006年3月至2010年3月不稳定型心绞痛患者175例，完全随机分为治疗组（58例）、对照Ⅰ组（52例）和对照Ⅱ组（65例）。在常规治疗的基础上，治疗组应用LMWH联合银杏达莫注射液治疗，对照Ⅰ组应用LMWH治疗，对照Ⅱ组应用银杏达莫注射液治疗，疗程均为2周。比较3组临床症状改善、心电图缺血改善及复合终点事件发生情况。结果治疗后治疗组临床症状改善总有效率、心电图缺血改善总有效率、复合终点事件发生率方面明显优于对照Ⅰ组和对照Ⅱ组[分别为82．76％（48／58）比65．38％（34／52）、63．08％（41／65），77．59％（45／58）比55．77％（29／52）、53．85％（35／65），18．97％（11／58）比36．54％（19／52）、35．38％（23／65）]，差异有统计学意义（P〈0．05或P〈0．01）。结论LMWH联合银杏达莫注射液可以明显改善不稳定型心绞痛患者心肌供血，缓解临床症状，疗效明显优于单用LMWH或银杏达莫注射液。

Objective To study the therapeutic effect of low-molecule heparin （LMWH） and Ginkgo-dipyidamolum injection for unstable angina （UA）. Methods One hundred and seventy-five cases with UA were chosen from March 2006 to March 2010, completely randomly divided into treatment group （58 cases） and control group Ⅰ （52 cases） and control group Ⅱ （65 cases）. On the basis of routine therapy, control and treatment groups for UA patients were established, and for experimental group, 58 patients were treated with both LMWH and Ginkgo-dipyidamolum injection. Results Statistically, compared with control group, the treatment of experimental group is more effective on aspects as follows：easing clinical symptoms, allaying myocardial ischemia diagnosed by electrocardiogram, and preventing composite of non-fatal stroke, myocardial infarction and cardiovascular death [ 82.76% （48/ 58 ） vs 65.38% （34/52） ,63.08% （41/65） ;77.59% （45/58） vs 55.77% （29/52） ,53.85% （35/65） ;18.97% （11/58） vs 36.54%（19/52）,35.38%（23/65）,P〈0.05,P〈0.01]. Conclusion LMWH and Ginkgo-dipyidamolum injection are more effective than that of either LMWH or Ginkgo-dipyidamolum injection on abirritating myocardial blooding and relieving clinical symptom.